BIO-KOREA
13.5.2020 06:36:05 CEST | Business Wire | Press release
The BIO KOREA Organizing Committee announced it will hold the BIO KOREA 2020 International Convention scheduled for May 18–23 as an online convention instead of an in-person event for this year.
The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
BIO KOREA 2020 Online Convention
- Date: May 18 09:00 to 23 18:00 (KST)
- Point of Access: www.biokorea.org
- Program: Online Business Forum with Partnering, Virtual Exhibition, e-Conference, Invest Fair, Job Fair
Online Business Forum with Partnering
BIO KOREA 2020 Online Convention will focus on the virtual collaboration with its Partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential. International participation continues to grow. Numerous companies from 20+ countries are already joined and expected to showcase their advanced technologies at BIO KOREA 2020.
Definitely expecting to be a place where various kinds of discussion will be held, with Korean companies as not just the companies which are leading bio industry in Korea such as LG Chem Life Science, Samsung Biologics, Celltrion, and Hanmi Pharmaceuticals, etc., also promising SMEs like Organoid Science, YBRAIN, and Amyloid Solution are attending to foster their business. And 24-hour meeting slots will let strengthen your digital network across time zones.
Virtual Exhibition
The new format includes Virtual Exhibition where has set to show the cutting-edge technologies and products of exhibitors in various ways such as Digital Scan, Animation, 360° VR, and so on. 350+ exhibitors, from start-up to the global enterprise, will be at BIO KOREA's virtual exhibition and also there will be COVID-19 Special Zone to introduce South Korea's effective diagnostic tests, high-tech medical technology, and protocols.
e-Conference
The conference of BIO KOREA will also come with the online format under the theme of “A New Paradigm in the Age of Data Science” including expert-level content focused on the most pressing industry topics including COVID-19, Vaccine, Alzheimer’s Disease, Electroceutical, Digital Pathology, Digital Therapeutics, AI (Artificial Intelligence). BIO KOREA 2020’s e-Conference, covering 13 topics with 90+ speakers, will bring the most up-to-date conversations in biopharma to your home office.
Invest Fair
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their superior technology and investors to the companies’ vision and strategy. Along with online hosting, it maintains its attendance by impressive lineups of 24 companies such as GC Greencross, Celltrion, Tium BIO, and ABL Bio.
Job Fair
Aiming to place its main objective in recruiting talented individuals amongst undergraduates and postgraduates searching for job vacancies in bio industry, companies participating in Job Fair will share their success tips in various fields. Amid current bleak jobs pictures, about 30 companies are attending with 150+ job openings.
Lastly, BIO KOREA remains committed to amplifying the industry’s efforts to develop solutions for patients. In response to the COVID-19 pandemic, the special sessions dealing with its diagnostic kits, therapeutics and vaccines, also sharing the cooperation among the governments, industries are prepared. Jerom Kim from IVI will deliver the Keynote speech for the COVID-19 special session.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005997/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom